Down Syndrome and Acute Lymphoblastic Leukemia Association
Yes, Down syndrome is strongly associated with acute lymphoblastic leukemia (ALL), with children with Down syndrome having a 10- to 20-fold increased risk of developing ALL compared to children without Down syndrome. 1, 2
Magnitude of Risk
- Children with Down syndrome face a significantly elevated risk of ALL, with some studies reporting up to a 20-fold increased incidence compared to the general pediatric population 3, 4
- ALL represents one of the two major leukemia types affecting children with Down syndrome, alongside acute myeloid leukemia (AML) 1, 5
- This association is well-established in clinical guidelines, with trisomy 21 (Down syndrome) formally recognized as a predisposition to both myeloid and lymphoid neoplasms 1
Unique Biological Features of DS-ALL
The biology of ALL in Down syndrome differs substantially from non-Down syndrome ALL, with distinct molecular characteristics:
- Approximately 50-62% of DS-ALL cases harbor CRLF2 (cytokine receptor-like factor 2) rearrangements, compared to much lower frequencies in non-DS ALL 4, 6
- IKZF1 deletions occur in approximately 35% of DS-ALL patients and represent a strong independent predictor of poor outcome, with 6-year event-free survival of only 21-45% versus 58-95% in those without IKZF1 deletions 6
- JAK2 mutations are present in approximately 15% of DS-ALL cases 6
- Genomic landscape analysis has identified 15 distinct molecular subtypes of DS-ALL, with marked enrichment of CRLF2-rearranged, IGH::IGF2BP1, and C/EBP altered subtypes 7
Inherited Genetic Susceptibility
Beyond trisomy 21 itself, additional inherited genetic variants modify ALL risk in Down syndrome:
- Genome-wide association studies have identified four susceptibility loci at genome-wide significance: near IKZF1, in CDKN2A, in ARID5B, and in GATA3 3
- The CDKN2A risk locus shows significantly higher penetrance in children with Down syndrome compared to non-DS ALL (odds ratio 1.58), indicating gene-environment interaction between trisomy 21 and inherited variants 3
- This increased penetrance of CDKN2A risk alleles persists across different molecular subgroups, including those with and without CRLF2 overexpression 3
Clinical Outcomes and Treatment Challenges
Children with DS-ALL face inferior outcomes compared to non-DS ALL due to both higher treatment-related mortality and increased relapse rates:
- DS-ALL patients demonstrate increased vulnerability to treatment-related toxicity, requiring careful dose modifications and supportive care 8, 2
- Treatment-related mortality is significantly elevated in DS-ALL compared to non-DS ALL 2
- Relapsed DS-ALL has particularly poor outcomes, with limited salvage options due to cumulative toxicity concerns 2
- The BCR::ABL1-like subset within CRLF2-rearranged DS-ALL is associated with inferior event-free survival even after adjusting for known clinical risk factors 7
Key Clinical Pitfalls
- Do not assume DS-ALL has favorable outcomes like DS-associated myeloid leukemia (ML-DS): While ML-DS has excellent cure rates due to chemotherapy sensitivity, DS-ALL has worse outcomes than non-DS ALL 5, 2
- IKZF1 deletion status should be assessed: This represents the strongest independent predictor of outcome and may warrant risk-group stratification in future protocols 6
- CRLF2 status alone does not predict prognosis: Despite high frequency, CRLF2 rearrangements without additional risk factors like BCR::ABL1-like signature do not independently predict worse outcomes 6, 7